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Fennel (Foeniculum vulgare Mill.) mature fruit (commonly known as seeds) and essential oil of fennel are widely used as
flavoring agents in food products such as liqueurs, bread, cheese, and an ingredient of cosmetics and pharmaceutical products.
Moreover fennel infusions are the classical decoction for nursing babies to prevent flatulence and colic spasm. Traditionally in
Europe andMediterranean areas fennel is used as antispasmodic, diuretic, anti-inflammatory, analgesic, secretomotor, secretolytic,
galactagogue, eye lotion, and antioxidant remedy and integrator. Topically, fennel powder is used as a poultice for snake bites. In
Asian cultures fennel was ingested to speed the elimination of poisons. As one of the ancient Saxon people’s nine sacred herbs,
fennel was credited with the power to cure. Fennel was also valued as a magic herb: in the Middle Ages it was draped over
doorways on Midsummer’s Eve to protect the household from evil spirits. Recently because of estragole carcinogenicity, fennel
has been charged to be dangerous for humans especially if used as decoction for babies. But this allegation do not consider the
remedy is prepared as a matrix of substances, and recent researches confirm that pure estragole is inactivated by many substance
contained in the decoction.
1. Introduction
Fennel (Foeniculum vulgare Mill.) belongs to the family of
Apiaceae, and is an annual, biennial, or perennial herbaceous
plant, depending on the variety, which grows in good soils
from sunny mild climatic regions and is a well-known
aromatic plant species. Foeniculum vulgare has two com-
mercially important fennel types: bitter fennel, Foeniculum
vulgare Mill. subsp. vulgare var. vulgare, and sweet fennel
Foeniculum vulgare subsp. vulgare var. dulce. Several fennel
parts are edible (bulbs, leaves, stalks, and fruits). Mature
fruit (commonly known as seeds) and essential oil of
fennel are used as flavoring agents in food products such
as liqueurs, bread, cheese, and an ingredient of cosmetics
and pharmaceutical products. Moreover fennel infusions
are the classical decoction for nursing babies to prevent
flatulence and colic spasms [1–4]. Traditionally in Europe
and Mediterranean areas fennel is used as antispasmodic,
diuretic, anti-inflammatory, analgesic, secretomotor, secre-
tolytic, galactagogue, eye lotion, and antioxidant remedy and
integrator.
It is thus of extreme importance the efficacy, quality,
and most of all toxicology of fennel based remedies and
preparations is assessed, namely, when estragole (Figure 1),
one of its constituents, has been notoriously declared to be a
carcinogen substance [5].
The European Food Safety Authority (EFSA) suggested
the so-called Margin of Exposure (MOE) to be used to set
priorities in risk management with respect to compounds
that are both genotoxic and carcinogenic [6]. MOE is
defined as the ratio between the lower confidence limit of
the benchmark dose that gives 10% extra cancer incidence
(BMDL10) and the estimated daily intake (EDI) for estragole
is estimated from different food sources 0.07mg/kg bw/day
[7]. The MOE for pure estragole amounts to 129–471
and according to EFSA a MOE lower than 10.000 can be
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Figure 1: Estragole structure.
considered a priority for human risk [6, 8]. We contend that
study of estragole as a single substance can be misleading
and misrepresents the activity of this substance when present
in the form of a complex herbal extract. This brings into
question the validity of studies of pure compoudns that are
taken outside of the context of the normal food matrix,
which should serve as the benchmark for testing levels in
human carcinogenicity studies.
2. Chemical Constituents of Fennel
According to the 2nd edition of the European Pharma-
copoeia monograph, sweet fennel contains not less than
2.0% v/m of essential oil, calculated with reference to the
anhydrous drug. The essential oil is constituted mainly
by anethole (80%) (a substance with supposed anticancer
properties), it contains not more than 10% estragole and
not more than 7.5% fenchone [9]. Other minor constituents
may be present including: R-pinene, limonene, β-pinene, β-
myrcene, and p-cymene [9–11]. Furthermore, sweet fennel
contains other nonvolatile constituents such as flavonoids
and coumarins [12, 13], which have not received till now suf-
ficient attention with regard to pharmacological properties
[14].
In a paper the essential oil yield of bitter fennel fruits was
12.5 v/w, whereas 1.8 v/w volatile fraction (corresponding
to plant material) was obtained by hydro-distillation of the
plant infusion which is equivalent to 14.5% of the initial
fennel essential oil. The main constituents of the volatile
fraction of the fennel infusion were (hydro-distillation/SPE):
trans-anethole (56.4%/58.4%), fenchone (36.2%/39.5%),
and estragole (2.5%/2.2%); which were also the major
compounds of the genuine bitter fennel essential oil. In
infusions the proportion of ethers versus ketones was shifted
significantly towards a higher of the latter, compared with the
essential oil obtained from the fruits [15].
Generally prepackaged teabags marketed contain unbro-
ken and/or crushed fruit or powdered drug. The use of
unbroken fruit to prepare infusions is incorrect: because
crushed or powered fruit gradually lose their essential oil
content during aging [16], like many herbal remedies.
Many phytochemical researches have been conducted so
far to investigate the chemical composition of fennel essential
oil with different results: depending on the time of harvests,
conservation, region, and area of cultivation. The major
components of fennel are phenylpropanoid derivatives:
trans-anethole and estragole (= methyl chavicol), and then
alpha-phellandrene, limonene, fenchone, and alpha-pinene
[17–20].
Essential oil composition depends upon internal and
external factors affecting the plant such as genetic structures
and ecological conditions; agricultural practices also have
critical effects on yield and oil composition in the essential oil
crops, although essential oil has some main components that
can variate significantly according to the maturation period
[21].
Piccaglia and Mariotti [19] indicated the presence of five
different chemical groups in the essential oils isolated from
fresh aerial parts of wild fennel collected in thirteen Ital-
ian areas: (1) trans-anethole, estragole, alpha-phellandrene;
(2) trans-anethole, alpha-pinene, limonene; (3) estragole,
alpha-phellandrene; (4) estragole, alpha-pinene; (5) alpha-
phellandrene. About the chemical composition of fennel
fruits (= seeds) the phenylpropanoid fraction (80–89%) and
estragole (79–88%), dominated the fruit oil [18]. The relative
amount of trans-anethole in these oils were much lower than
those that characterize bitter fennel oils [22]. Some previous
studies on fennel fruits essential oils have also mentioned
estragole chemotypes in variable amounts (a variability in
the variety), where estragole alone dominates the oil, or is
present together with either trans-anethole or fenchone [18].
These results for the chemical composition of the essential
oils of fennel aerial parts and fruits, support the view of
Miraldi [7] that knowledge of fennel essential oils is still
not enough to distinguish accurately all the existing varieties
[18]. So it is very difficult to establish the effective amount
of essential oil, estragole, and other substance in different
industrial and homemade preparations. In a recent paper
[23] was studied the chemical composition of 3 organically
cultivated fennel cultivars: Foeniculum vulgare var. azoricum,
var. dulce and var. vulgare. Gas chromatography/mass spec-
trometry analysis of the essential oils revealed the presence
of 18 major monoterpenoids in all three cultivars but
their percentage in each oil were greatly different [23].
The two azoricum and dulce cultivars are similar in their
chemical composition but greatly different than the vulgare
cultivar: trans-anethole accounted for 61% and 46% in the
oil of azoricum and dulce cultivars, respectively, while it
accounted for only 5% in the vulgare cultivar. Estragole
was the major compound in the oil of the vulgare cultivar,
with a concentration of 58% compared to 12% and 6% in
the oils of azoricum and dulce cultivars, respectively [23].
The essential oils of two of the fennel cultivars, that is,
azoricum and dulce, showed dramatically higher antioxidant
activities than the essential oil of the vulgare cultivar [23].
The three oils contain similar concentrations of all other
major compounds excluding trans-anethole and estragole
suggesting that antioxidant activity is mostly related to the
concentration of trans-anethole [23]. One of the major
differences between the chemical structure of estragole and
anethole is the double bond of the propenyl side chain:
in anethole is conjugated with the aromatic ring while in
estragole it is nonconjugated [23].
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Figure 2: Bioactivation pathway of estragole.
3. Estragole Carcinogenicity In Vitro and
Its Metabolic Pathways
For flavonoids formation of reactive intermediates proceeds
by their enzymatic and/or chemical oxidation to quinone/
quinone methide type metabolites [21], that are reactive
alkylating intermediates. For alkenylbenzenes, including
estragole, methyleugenol, elemicin, safrole, and myristicin
the ultimate carcinogenic metabolites are their 1′-sulfooxy
derivatives which degrade to alkylating carbocations that
transformed in reactive substance, can give rise to DNA
adducts.
Estragole is known to be metabolized along a number
of pathways including O-demethylation (to give chavicol),
epoxidation of the double bond, 1′-hydroxilation, and
oxidative degradation of the side chain to carboxylic acids
[24]. Zangouras et al. [24] indicate that at least two pathways,
namely, O-demethylation and 1′-hydroxylation exhibit dose-
dependency in both mouse and rat. Thus the proportion of
the dose that undergoes O-demethylation declines in a dose-
dependent fashion and is accompanied by an increase in the
proportion of the dose that undergoes urinary elimination
[24]. This change presumably arises from saturation of
the enzyme systems responsible for O-dealkylation. The
corollary of this is that at higher doses a relatively greater
substrate level would be available for alternative metabolic
reactions such as 1′-hydroxylation [24]. In the mouse the
major route of estragole metabolism is via hydroxilation
at the 1′ position [20, 25, 26]; producing derivatives with
increased carcinogenic potential. Sulfuric acid esters of these
compounds have been strongly implicated as the major
ultimate electrophilic and carcinogenic metabolites in vivo.
Thus mouse liver cytosols contain 3′-phosphoadenosine 5′-
phosphosulfate-dependent sulfotransferase activity for 1′-
hydroxysafrole and 1′-hydroxydehydroestragole [18, 19, 27].
The well-known bioactivation pathway of estragole pro-
ceeds by initial metabolic hydroxylation by cytochrome P450
enzymes, leading to the production of the proximate car-
cinogen 1′-hydroxyestragole, that by involvement of sulfo-
transferases is converted to the ultimate 1′-sulfooxyestragole;
an instable substance that degrades to a reactive carbocation
binding to different endogenous nucleophiles and inducing
the production of DNA adducts [28], in particular hepatic
macromolecular adducts [29]; and these as shown in rodents
when given as a pure compound and at high dose-levels-
induced hepatomas [30] (Figure 2).
To study bioactivation and detoxification of suspect toxic
substance derived from estragole the PBK (Physiologically
based kinetic) model was extended to a physiologically based
dynamic (PBD) model, by which predict the formation of
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DNA adducts in the liver of male rats [31]. A PBD model
was developed by extending the PBK model through linking
the area under the curve for 1′-hydroxyestragole formation
predicted by the PBK model to the area under the curve
for 1′-hydroxyestragole in in vitro incubations with rat
hepatocytes exposed to 1′-hydroxyestragole [26]. The PBD
model thus obtained, was validated by in vivo experimental
data on DNA adducts formation in the liver of mice exposed
to estragole, since data from rat were not available [26].
Literature reports the formation of 1 adduct in 10.000–
15.000 DNA nucleotides after a single i.p. injection of about
400mg estragole/kg bw/day to female CD-1 mice [32]. At
this dose the PBD model predicts the formation of E-3′-
N2-dGuo, the major estragole DNA adduct formed [33] in
the liver of rat at a level amounting to 4 adducts in 10.000
nucleotides. Thus, levels of DNA adducts formation in the
two studies are within the same order of magnitude [26].
The slight difference can be explained by the difference in
the experimental design of the two studies. At dose levels
that match the available estimates for the daily intake of
estragole, amounting to 0.01mg/kg bw [34] and 0.07mg/kg
bw estragole [35], the PBD model predicted amounts of E-
3′-N2-dGuo DNA adduct formed of, respectively, 2 and 12.8
in 108 nucleotides.
Estragole, like other allylbenzene analogs in the liver,
is subject to biotransformation which can generate reactive
electrophilic intermediates; the allylic epoxides form readily
in vitro, but can be rapidly further metabolized to less toxic
dihydrol or glutathione conjugates [36]. Epoxide metabolites
of allylbenzene are highly reactive and the metabolic pathway
initiated by epoxidation has an equivalent potential for
biochemical damage to that posed by the 1-hydroxylation
pathway [36].
Using levels of epoxides 100-fold the maximal exposure
to estragole in human diet in cells of different species,
human liver cells had by far the highest allylic epoxide
hydrolase activity, seven to 10 times higher than that seen
in rat liver; probably the level of physiological protection
against these reactants in humans, is higher than in other
animal species [36]. Dihydrodiol derivatives were recovered
at significant levels in urine of animals fed estragole, so
dihydrodiol metabolites presumably represent end products
of the epoxidation pathway, and carried out in a test
accounted for up to 30% of the total metabolic clearance
of estragole [37, 38]; an important outcome because it is
approximately the same contribution to the overall metabolic
clearance provided by the most studied 1′-hydroxylation
pathway.
Recent studies have shown that 1′-hydroxyestragole
glucuronide generation is a major pathway of estragole
metabolism in rats and mice, which is dose-dependent and
accounts for as much as 24% and 33% of the estragole
urinary metabolites in rats and mice, respectively [39].
1′-hydroxyestragole and derivated glucuronides are
major metabolites formed by human hepatocytes in vitro.
By 24 h, about 12.5% of estragole is converted to 1′-
hydroxyestragole glucuronide by human liver cells [39].
Hence, glucuronidation represents another significant route
of detoxification of estragole in all species studied and
humans too, that can be activated, although in a different
way, by many different flavonoids that are part of the
fennel matrix decoction. As shown in the paper of Iyer
[39] 1′-hydroxyestragole glucuronidation in 27 individual
human liver samples significantly (P < 0.05) correlated
with the glucuronidation of other UGT2B7 substrates (mor-
phine and ibuprofen). Iyer et al. [39] have determined
that 1′-hydroxyestragole, which is the precursor to 1′-
sulfooxyestragole, the active metabolite of estragole believed
to be carcinogenic, is conjugated mainly by UGT2B7 using
cDNA expressed UGT isoforms and correlation studies with
other UGT2B7 substrates. UGT1A9 and UGT2B15 were
also found to conjugate 1′-hydroxyestragole; this implies
that concomitant chronic intake of therapeutic drugs and
dietary components that are UGT2B7 and/or UGT1A9
substrates (which are both expressed in the gastrointestinal
and liver tissues) may interfere with estragole metabolism
[40, 41]. Because the carcinogenicity of 1′-hydroxyestragole
is clearly dependent on the balance between formation of
the active metabolites, (1′-sulfooxyestragole) and epoxides,
and detoxification by glucuronidation; marked interindi-
vidual differences in the rate of 1′-hydroxyestragole glu-
curonidation, may have important toxicogenetic implica-
tions. The screen of 1′-hydroxyestragole glucuronidation in
liver samples from 27 individuals indicated a significant
intersubject variability, with a coefficient of variation of 42%
[39].
4. The Issue of Estragole Carcinogenicity
Interest in the safety of estragole as a food flavoring
stems from observations on the closely related compound
safrole, which is both hepatotoxic and hepatocarcinogenic in
rodents. Estragole has been shown to be an hepatocarcinogen
in preweanling CD-1 mice and preweanling B6C3F1 mice
[30, 42]. Administration of 0.23 or 0.46 (w/w) estragole in
the diet of CD-1 mice for 12 months resulted in hepatomas
in 56 and 71% of the mice [30]. About these results it is
probably important to underline that in the first paper [42]
the incidence of hepatomas in CD-1 mice (verum group),
receiving only the vehicle (trioctanoin), was 12%; in a second
group [42], 24% of males and 2% of female of CD-1
mice that received trioctanoin were bearing an hepatoma;
in another experiment 26% of males that received only
trioctanoin by i.p. injection after 12 months had hepatomas,
and even 12% of not injected male B6C3F mice developed
a hepatoma [30]. We think these data should stimulate
reflection about real worth of these experiments in the
evaluation of estragole and its derivatives, that probably has
been overestimated.
Anthony et al. [27] in his paper reports the metabolism
of [14C] estragole in rats (by oral intubation) and mice (by
i.p. injection) studying the variation of metabolism with
dose over the range 50 g to 1000mg/kg in both species. In
mice elimination was essentially complete within 24 hr, and
in rats receiving a high dose (500–1000mg/kg), there was
significant excretion on day 2. In both species the main route
of elimination of very low doses was exhalation of 14CO2
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and urine was a minor route [27]. In these experiments as
the dose level increased, the exhalation of 14CO2, expressed
as a percentage of the dose fell, while excretion in the urine
rose. In rats and mice the proportion of urinary 14C present
as 1′-hydroxyestragole and 4-methoxy-cinnamyl alcohol rose
significantly with dose. The excretion of acidic metabolites,
indicated by the percentage of urinary 14C extracted into
ether at pH 1.0 was unaffected by dose size in the mouse
and fell in the rat. The elimination of polar unextractable
metabolites fell significantly with increasing dose in both
species [27]. It is of paramount importance to consider the
implications of these results in respect to the papers of Miller
and Drinkwater [30, 42], because the dose they administered
to animals must be contrasted to the estimated human daily
intake of only 70 μg (approximately 1 μg/kg). (Flavor and
Extract Manufacturer’s Association, 1978).
In fact the hepatocarcinogenicity of estragole in mice has
been clearly related to its conversion to 1′-hydroxyestragole,
but factors influencing its formation may also cause a related
variation in the incidence of tumors and in this context
the nonlinear relationship between dose, animal species,
and elimination of the 1′-hydroxy metabolite is important
[33], particularly in connection with human metabolism.
Sangster [25] showed in 2 healthy individuals, administered
1mg/day of estragole, the excretion of 1′-hydroxyestragole
glucuronide in human urine amounts to only 0.3% of the
administered dose (0.02 nmol/kg 24 hr), a value far lower
than that obtained in rodents even at the lowest doses
(0.05mg/kg body weight; 1′-hydroxyestragole excretion in
24 h in rat 4.5 nmol/kg; in mice 4.5 nmol/kg) [27]. Probably
rodent carcinogenicity tests overestimate the risk of estragole
carcinogenicity.
Another important difference in estragole metabolism
between mice and humans is highlighted by an examination
of dose dependency. In this case, the genotoxic metabolite
found in urine, 1′-hydroxyestragole, can be used as a
indicator of interspecies differences. In mice increasing doses
of estragole leads to increasing levels of the metabolite
in urine: low doses (0.05–50mg/kg body weight) led to
1.3–5.4% 1′-hydroxyestragole; high doses (500–1,000mg/kg
body weigh), led to 11.4–13.7% 1′-hydroxyestragole. In
humans, the amount of 1′-hydroxyestragole in the urine
remained constant at 0.2–0.4% throughout a wide dosage
range (1–250mg estragole or 0.01–5mg/kg body weight)
[25]. A subsequent study on the metabolism of trans-
anethole found that it was eliminated by humans 6 to 9 times
quicker than by mice [43].
Consideration of these issues (dose, administration form,
and differences in metabolism between species) raises doubts
about the conclusion that fennel seed can be “reasonably
anticipated to be a human carcinogen” [44], It is clear that
human and animal metabolism cannot be directly compared
but we think data should deserve attention.
In an experiment with male Sprague-Dawley rats (180–
200 g) using a CCl4 model, using pure fennel essential oil
extract was demonstrated a protective effect against the
toxicity induced by CCl4 in rats. Which constituent(s) of the
extract is responsible for this effect was not fully investigated
[45]. The anticarcinogenic activity of fennel essential oil
considered as a matrix of substance is confirmed by another
recent paper using a methanolic fennel extract, that showed
a mean± standard deviation 50% inhibitory concentrations
were 50 ± 0.03μg/mL for the MCF7 breast cancer cell line
and 48 ± 022μg/mL for the Hepg-2 liver cancer cell line.
The significant increase in malondialdehyde levels and the
significant decrease in catalase activity and glutathione con-
tent in liver and tumor tissue in mice bearing Ehrlich ascites
carcinoma improved after administration of the extract. In
vitro pretreatments with fennel essential oil significantly
inhibited the frequencies of aberrant metaphases, chromo-
somal aberrations, micronuclei formation, and cytotoxicity
in mouse bone marrow cells induced by cyclophosphamide
and also produced a significant reduction of abnormal
sperm and antagonized the reduction of cyclophosphamide-
induced superoxide dismutase, glutathione, catalase and
inhibited increased malondialdehyde activities content in
the liver [46]. In a study evaluating the efficacy of a
fennel seed methanolic extract for its antioxidant, cytotoxic,
and antitumor activities and for its capacity to serve as
a nontoxic radioprotector in Swiss albino mice, and on
different types of human cell lines in vitro, was also assessed
the natural antioxidant compounds of the extract for use in
industrial application [47]. The extract showed remarkable
anticancer potential against a breast cancer cell line (MCF7)
and liver cancer cell line (Hepg-2). It also showed strong
free radical-scavenging activity (100%). In the conclusions
the authors stated that could be used as a safe, effective,
and easily accessible source of natural antioxidants to
improve the oxidative stability of fatty foods during storage
[47].
Nevertheless, has been recently demonstrated a direct
carcinogenicity of estragole and found in vitro low levels
of DNA adducts, with a significant dose response up to
1000mM, suggesting the possibility of a direct-acting mech-
anism of adduction [48]. Experiments were also conducted
to evaluate the persistence of DNA adducts produced by
estragole in V79 cells, after a 25-hour recovery period. The
results indicated that adducts are still present after this
recovery period, suggesting that at these levels (1000mM)
repair is not efficient. And was shown that estragole did
not induce apoptosis in all the assays performed for all
concentrations tested, except at the highest concentration
of 2000mM [48]. For this dose and a 24-hour period
estragole induced apoptosis to a limited extent, compared
with the positive control. The MTT assays also show no
significant cytotoxicity (above 50% cellular viability) and the
authors concluded that estragole does not induce apoptosis
at physiologically relevant doses.
In summary, according to the results obtained, it seems
that the genotoxicity of estragole in vitro at high doses may
ensue in part from direct adduction of DNA which can lead
to alkali-labile sites in DNA, resulting in tails in the comet
assay, and SCE, due to DNA strand-breaks. Nevertheless,
the authors state that doses necessary to induce a genotoxic
response are far from physiologically relevant human doses,
and therefore the relevance of these adducts for tumor
induction in humans in vivo needs to be further clarified
[48].
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5. Inhibition of DNA Adduct Formation
Inhibition of Carcinogenesis
Recently has been demonstrated that formation of DNA
adducts by 1′-hydroxyestragole and cofactor for SULT-
mediated conversion could be inhibited by basil extract,
the same result was then confirmed in intact human
hepatoma cells [49]. This result suggests the likelihood that
bioactivation and carcinogenicity may be much lower when
estragole is administered at low dose and in a natural matrix.
In experiments using basil derivatives the flavonoid
nevadensin, it was able to efficiently inhibit the sulfotrans-
ferasemediated conversion of 1′hydroxy alkenylbenzenes
to the corresponding 1′-sulfooxy metabolites responsible
for the DNA adduct formation [28]. Further experiments
also indicated that nevadensin-mediated inhibition of
the formation of the ultimate carcinogenic metabolite of
estragole, occurs without reducing the capacity to detoxify
1′-hydroxyestragole via glucuronidation or oxidation [28].
This indicates a potential shift in the phase II metabolism of
alkenylbenzenes upon coexposure with nevadensin and/or
other flavonoids capable of sulfotransferase inhibition [26].
Assuming a 1% instead of a 100% uptake of nevadensin
(similar to a nevadensin: estragole molar ratio of 0.01),
the model still predicts about 17% and 43% inhibition of
1′-sulfooxyestragole formation as compared to control in rat
and human, respectively [28], so it appears muchmore active
in humans. In the paper of Alhusainy et al. [28] has been
shown that at a molar ratio of nevadensin to estragole of
0.06, at which the two compounds are expected to be present
in basil, the model predicts an almost complete inhibition of
1′-sulfooxyestragole formation in the liver of male rat and
human when assuming 100% uptake of nevadensin.
In the paper of Rietjens [26] even a 1% nevadensin
bioavailability at a dose of 50mg/kg bw of estragole, a dose
level in the range of the BMDL10 for tumor formation, dos-
ing of an equimolar quantity of nevadensin, is predicted to
result in only 2.4% 1′-sulfooxyestragole formation compared
to the amount formed in the uninhibited situation. Our
group has isolated and identified nevadensin also in different
fennel extracts, so we think nevadensin probably has the
same protective effect in fennel extracts too [50].
Moreover using 60 different basil fractions, besides the
one identified as nevadensin, about half were able to inhibit
SULT activity with different potency [29], and so it can
be extrapolated that all together can completely stop SULT
activity.
A significant difficulty in evaluating the metabolic,
biochemical, and toxicological data for estragole as well
as other alkenylbenzenes is that human exposure to these
substances results from exposure to a complex mixture of
food, spice, and spice oil constituents whichmay significantly
impact the biochemical fate and toxicological risk of the
alkenylbenzenes [51].
Recently Alhusainy et al. [51] have shown that given
a normal diet may contain a variety of SULT inhibitors,
experiments were performed to assess the effect of combined
flavonoid exposure on SULT activity as well as on oxidation
of 1′-hydroxyestragole to 1′-oxoestragole. To this end a test
mixture was defined that mimics a realistic dietary flavonoid
mixture and included four flavonoids that were found to be
abundant in alkenylbenzene-containing herbs and spices and
able to inhibit SULT activity, namely: quercetin, kaempferol,
apigenin, and nevadensin, the latter being previously iden-
tified as a potent SULT inhibitor present in basil [29]. The
compounds were not cytotoxic to HepG2 cells under the
conditions used in these experiments and revealed that a
significant reduction in the formation of E-3′-N2-dGuo
compared to control (no flavonoid(s)) is observed in the
human HepG2 cells following coadministration of 50M of
the substrate 1′-hydroxyestragole and 23M of a flavonoid
mixture containing quercetin, kaempferol, myricetin, api-
genin, and luteolin (each at a concentration corresponding
to its relative contribution in the diet). Altogether, the data
indicates a shift metabolism from sulfonation and oxidation
to glucuronidation which is a detoxification pathway for
1′-hydroxyestragole [51]. Finally, it is worth noting that
even when the concentration of estragole was increased
1000 fold keeping the concentrations of the SULT inhibiting
flavonoids at the values defined in the paper, the percentage
inhibition of 1′-sulfooxyestragole formation remains the
same as obtained at the 1000-fold lower dose of estragole.
This is a characteristic of noncompetitive inhibition, where
the level of inhibition depends only on the dose of the
inhibitors [52].
In our opinion the same effect can be deduced for
fennel decoction too, because flavonoids (nevadensin) are
a very common substance in plants and can be easily
extracted by herb decoction. In fact flavonoids induce
detoxifying enzymes such as NAD(P)H: quinone oxidore-
ductase 1 and glutathione S-transferase which represent
important defense mechanism against electrophilic toxicants
and oxidative stress [49, 53]. Their prooxidant activity can
result in the formation of highly reactive quinone/quinone
methide metabolites which fulfill the requirements for
electrophilic responsive elements-mediated induction of
detoxifying enzymes [26]. It has been demonstrated that
the electrophilic responsive elements-mediated response
to flavonoids is increased in cells with reduced cellular
GSH levels and decreased in cells with increased levels of
GSH, supporting a role for the flavonoid quinone/quinone
methides in electrophilic responsive elements activation [49,
53]. In infant fennel decoction formulas, the content of
estragole was found to range from 241 to 2058mg L−1 in
infusions obtained following the same preparation mode
(in 100mL of boiling water) [54]. Authors analyzing these
data and taking into account estragole concentration data
and applying an approach similar to that used by the ESCO
Working Group by a lower estimate of exposure showed
the daily consumption of three cups (100mL) of the tea
(2.25 g of comminuted seeds) had the highest estragole level
(2058 μg L−1, teabag product no. 7; amount of estragole in
a tea portion 206 μg) gave place to an exposure of 10 μg/kg
bw/day; from this exposure level, they calculated MOE
values ranging from 870 to 3210, [54] still a concerning
number especially if considered that the decoctions are used
for treatment of infant colics. Nevertheless in our opinion
because fennel seeds decoctions are a very common remedy
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used by Italian mothers and if we accept the fact that is an
effective hepatocarcinogenic substance, liver pediatric cancer
incidence should rise, while in Italy (and in all over the
world too) hepatic tumors are extremely rare in children.
The Italian official AIRTUM [55] database included only 20
new cases of hepatomas in 1998–2002 in children (age 0–14),
corresponding to 1% of incident pediatric neoplasms and
incidence trends in 1988–2002 in Italy is−4% [55]. We think
these data can confirm that fennel decoction use in infants
do not rise significantly the risk of primary liver cancer.
6. The Concept of Carcinogenicity
Although international variations in diet and cancer indicate
that diet is an important risk factor for many cancers,
it has been difficult to ascribe a clear role in cancer
causation to exposure to specific individual chemicals or
mixture of chemicals [56]. So far, only alcohol intake
(cancer of the oral cavity, pharynx, esophagus, and breast)
and food contaminated with aflatoxins have clearly been
documented as risk factors in humans [57]. Since evidence
of carcinogenicity in laboratory animals is generally taken
as an indication of potential human carcinogenic hazard,
much emphasis is given to the interpretation of findings
of animal carcinogenicity and the extrapolation of such
findings to humans [56]. The first step in the carcinogenicity
hazard identification is to establish whether or not the fennel
decoctions are carcinogenic, so we have to establish if we
are speaking of pure estragole or a decoction containing
estragole and other substances (flavonoids).
Decision about carcinogenicity is generally based on a
standard two-year carcinogenicity bioassay in rodents but
we think that important evidence should be based on
epidemiological data that probably give the definitive answer
to the problem. In a recent paper [58] that should be
considered a preferred approach to establish carcinogenicity
of food basing on data available from animal dose-response
analyses and human exposure, has been established by
important international bodies (WHO, EFSA, ILSI Europe)
a consensus about MOE (margin of exposure) but in the
same paper it has been stated that MOE can be used only
for prioritisation of risk management actions although the
conference stated the difficulty to interpret it in term of real
health risk for humans.
There are a number of issues that are central in this step
[56]. First, it is important to decide whether the observed
tumors in animal experiments are biologically relevant for
humans based on the mode of action. So it is fundamental
to understand how the toxic substance work, and establish
if it is genotoxic or a carcinogen nongenotoxic, the so-
called: MOA (mode of action), and site or sites of tumor
formation. Second, it must be ascertained whether the
existing toxicokinetic and toxicodynamic data are sufficient
to reach a definitive conclusion about the likely shape of the
dose-response curve for the carcinogenic effect. Especially
for food and herbal derivatives it may be particularly
difficult. Thirdly, data should be sought, in addition to those
from traditional genotoxicity studies, that contribute to an
understanding of the mode/mechanism of action. Then any
possible influence of nongenotoxic processes, for example,
hyperplasia, on the dose-response relationship should be
addressed [56]. Finally, it is important to identify data
which suggest whether or not there may be one or more
subpopulations with special sensitivity/susceptibility to the
carcinogenic effect (e.g., dependent on life-stage, gender, and
genetic polymorphisms) [56].
Since such judgments in practice almost always rely on
animal data, potency estimates are calculated from dose-
response information seen in animal experiments, these
being surrogates for the human situation [56]. Experimental
studies have revealed large variations, of up to 108–109, in the
doses of various carcinogenic substances needed to induce
tumors in animal experiments [59].
Although hazard identification is a crucial step in the risk
characterization process, it is important to recognize that it
would be inappropriate to evaluate the toxicity of chemicals
solely on the results of hazard identification, based merely
on the intrinsic toxicity of the molecule [60]. It happens that
data obtained in animals experiments carried out reaching
MTD (maximum tolerated dose) may have little biological
meaning since theymay induce pathophysiological responses
that are of little relevance for those that may be the result
of much lower doses [60]. A more qualified choice of the
dose range in animal studies would lead to a better and
meaningful extrapolation process from animals to humans.
The key for a correct extrapolation of animal data to humans
is the understanding of the mode of action of chemicals.
Unfortunately, this is not always the case, like is the case of
d-limonene and formaldehyde. D-Limonene is recognized as
an experimental carcinogen because causes nephropathy and
kidney tumors in male rats, through binding to α2u-globulin
in the kidney; but it is a globulin male rat specific and do not
represent any risk for human health [60, 61]. Formaldheyde
has been classified as a known human carcinogen, causing
several cancer, and particularly nasopharyngeal cancer and
leukemia, but innocuous if added to milk as a bacteriostatic,
because is rapidly transformed in spinacine, an innocuous
substance [62].
Traditionally, an uncertainly factor of 100 is used, based
on a 10-fold factor to allow for differences between average
humans and a 10-fold factor to allow for differences between
average humans and sensitive individuals [60]. A “false
negative” decision about the carcinogenicity of a substance
occurs when the bioassay fails to produce a statistically
significant increased tumor incidence when in fact the
chemical truly causes an increase in the tumor incidence
at the dose tested. This is a statistical limitation resulting
from the number of animals (generally 50) used per species-
sex-dose group. Using the estimate of the dose-response
trend obtained from other studies for each specified tumor
type/tissue site in animals and the standard error of the trend,
it is possible to estimate the approximate probability (power)
of detecting a statistically significant trend only as a function
of the sample size [63]. But if much more animals are used
per dose group the statistical analysis could change the results
and a substance can be categorized as carcinogenic, only
because the sample size is changed [63].
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7. Conclusion
In all of the animal studies reviewed, isolated, purified
estragole was used. Thus the findings give a toxicological
profile of this only molecule and not the profile risk of
the entire decoction. In humans estragole usually enters the
body as a component of fennel tea, or as a food that has
been seasoned with herb that contains many other substance
like nevadensin, epigallocatechine, other flavonoids, and
anethole, that have a protective role and so counterbalance to
the possible effect of pure estragole. In this context estragole
occurs in the form of an extremely complex phytochemical
mixture. If data about single constituent in vivo can be
used as basis for statements about a herb, then data about
other constituents should also be fully considered, because
we think it is the only way to establish definitively if a
substance is dangerous or not; and if it is a substance used
from many years and in particular subsets of consumers or
patients epidemiological data, when available, can help in
establishing, together with the real mode of use, the effective
risk for consumers.
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